Join XORTX for an Exclusive Live Investor Webinar
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) warmly invites investors to participate in an exciting live webinar and Q&A session scheduled for September 10 at 4:15 PM ET. This virtual event represents a unique opportunity for stakeholders to engage directly with the company's leadership and learn about pioneering therapies targeting gout and progressive kidney disease.
Insightful Discussion Led by Dr. Allen Davidoff
The webinar will be led by Dr. Allen Davidoff, the founder and CEO of XORTX, who is passionate about the company’s mission to address critical health needs through innovative treatments. Dr. Davidoff will provide an overview of XORTX's primary project, XRx-026 (XORLO™), aimed at those intolerant to allopurinol, a common treatment for gout. With plans for a New Drug Application (NDA) submission in the near future, XORTX anticipates that XORLO™ could tap into a significant market opportunity valued at an impressive USD $700 million annually.
XORTX's Commitment to Advancing Kidney Health
In addition to XORLO™, Dr. Davidoff will highlight the company's development of XRx-008, a promising treatment for autosomal dominant polycystic kidney disease (ADPKD). This candidate holds potential for orphan designation and exemplifies XORTX’s broader commitment to combating renal conditions. The presentation will also briefly cover additional innovative projects in their pipeline, including XRx-101 for acute kidney injury and XRx-225 targeting diabetic nephropathy.
Engage in a Live Q&A Session
Following the presentation, attendees will have the chance to engage in a live Q&A session with XORTX management. This interactive component allows participants to ask questions and gain deeper insights into the company’s strategies and product development efforts.
Register for the Free Webinar
Interested investors can register for the webinar at no cost. Ensure your spot by accessing the registration page. Additionally, questions can be submitted in advance or during the live session.
About XORTX Therapeutics Inc.
XORTX is devoted to transforming the landscape of kidney health through its clinically advanced pharmaceutical products. The company focuses on three main areas: treating gout with XRx-026, addressing ADPKD with XRx-008, and providing solutions for acute kidney injuries with XRx-101. Further, they’re in the process of developing XRx-225, a promising candidate for managing Type 2 diabetic nephropathy.
Innovation and Patient Focus
At XORTX, innovation is at the heart of everything they do. The company is dedicated to developing treatments that target abnormal purine metabolism and inhibit the production of uric acid, significantly improving patients' quality of life. With a strong vision, XORTX aims to address the unmet needs of patients suffering from gout and other impactful conditions.
Contact Information
If you would like more information or have any inquiries, please reach out to the company representatives listed below:
Allen Davidoff, CEO – adavidoff@xortx.com or +1 403 455 7727
Nick Rigopulos, Director of Communications – nick@alpineequityadv.com or +1 617 901 0785
For inquiries related to the webinar, please contact: XRTX@redchip.com or +1 407 644 4256
Frequently Asked Questions
What is the purpose of the XORTX investor webinar?
The webinar aims to provide insights into XORTX's innovative therapies and connect investors with the company's leadership.
Who will be presenting during the webinar?
The presentation will be led by Dr. Allen Davidoff, the CEO of XORTX Therapeutics Inc.
How can I submit questions for the Q&A session?
Questions can be submitted prior to or during the live Q&A session via the registration platform.
What products are being developed by XORTX?
XORTX is developing treatments for gout, ADPKD, and acute kidney injuries, among other conditions.
How can I register for the webinar?
You can register for the free webinar through the provided registration link in the announcement.
